FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases “The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives ...
Revvity, Inc. (NYSE:RVTY) shares are trading higher on Wednesday. The company announced today that the U.S. Food and Drug Administration has approved its Auto-Pure 2400 liquid handling platform, ...
Background: Diagnosis and treatment of latent tuberculosis infection (LTBI) is the most effective strategy to control tuberculosis (TB) among patients with HIV infection. The tuberculin skin test (TST ...
Revvity, Inc. RVTY is well-positioned for growth in the coming quarters, thanks to its strong product portfolio. The company benefits from a strong diagnostics franchise driven by newborn screening, ...
(RTTNews) - Revvity, Inc. (RVTY), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. tuberculosis (TB) test. "The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results